Tien Hoang, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
As a medical oncologist at the UW Paul P. Carbone Comprehensive Cancer Center, Dr. Hoang treats patients with lung cancer and head and neck cancer. Dr. Hoang is an Assistant Professor within the Hematology/Oncology Section, Department of Medicine. He received his medical degree from the University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam. Dr. Hoang completed his residency and fellowship training in Hematology/Oncology in New York City. From 2001 to 2005, he obtained further training in lung cancer in the University of Wisconsin's Academic Oncologist Training/Clinical Investigator Preparatory Program as part of the NCI K12 grant. Before joining the UW faculty in 2007, he was an Assistant Professor at the James Cancer Hospital and Solove Research Institute, Ohio State University.
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
State University of New York, Buffalo, NY
University of Wisconsin Hospital and Clinics, Madison, WI
Bronx Lebanon Hospital Center, Bronx, NY
University of Medicine & Pharmacy, Ho Chi Minh City, Vietnam, 1987
Dr. Hoang's research interests are in drug development and novel therapies for lung cancer and head and neck cancer. He is actively involved in clinical trials investigating molecularly-targeted agents in combination with chemotherapy and/or radiation therapy. He also interacts with basic scientists in development of new therapeutic agents. Dr. Hoang is a member of the American Society of Clinical Oncologists (ASCO), American Association for Cancer Research (AACR) and International Association for the Study of Lung Cancer (IASLC). He received the Eastern Cooperative Oncology Group (ECOG) Young Investigator Award and IASLC Fellowship Award.
Traynor AM Weigel TL Oettel KR Yang DT Zhang C Kim K Salgia R Iida M Brand TM Hoang T Campbell TC Hernan HR Wheeler DL .
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Apr 26;
[PubMed ID: 23628526]
Hoang T Dahlberg SE Schiller JH Johnson DH .
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer. 2013 Apr 20;
[PubMed ID: 23611404]
Hoang T Dahlberg SE Sandler AB Brahmer JR Schiller JH Johnson DH .
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012 Sep;7(9):1361-8
[PubMed ID: 22843087]
Hoang T Huang S Armstrong E Eickhoff JC Harari PM .
Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res. 2012 Apr 26;31:37
[PubMed ID: 22538017]
Hoang T Dahlberg SE Schiller JH Mehta MP Fitzgerald TJ Belinsky SA Johnson DH .
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012 Feb 20;30(6):616-22
[PubMed ID: 22271472]
O'Mahar SE Campbell TC Hoang T Seo S Kim K Larson MM Marcotte SM LoConte NK Traynor AM .
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 May;6(5):951-3
[PubMed ID: 21623267]
Traynor AM Schiller JH Stabile LP Kolesar JM Eickhoff JC Dacic S Hoang T Dubey S Marcotte SM Siegfried JM .
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer. 2009 Apr;64(1):51-9
[PubMed ID: 18701186]
Attia S Traynor AM Kim K Merchant JJ Hoang T Ahuja HG Beatty PA Hansen RM Masters GA Oettel KR Shapiro GR Larson MM Larson ML Schiller JH .
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol. 2008 Sep;3(9):1018-25
[PubMed ID: 18758305]
Hoang T Xu R Schiller JH Bonomi P Johnson DH .
Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 1;23(1):175-83
[PubMed ID: 15625371]
Hoang T Kim K Jaslowski A Koch P Beatty P McGovern J Quisumbing M Shapiro G Witte R Schiller JH .
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer. 2003 Oct;42(1):97-102
[PubMed ID: 14512193]
Hoang T Traynor AM Schiller JH .
Novel therapies for lung cancer. Surg Oncol. 2002 Dec;11(4):229-41
[PubMed ID: 12450559]
Hoang T Schiller JH .
Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev Anticancer Ther. 2002 Aug;2(4):393-401
[PubMed ID: 12647982]